Braun G G, Schywalsky M, Wölfel L, Müller H, Danner U, Albert R
Institut für Anästhesiologie, Universität Erlangen-Nürnberg.
Anaesthesiol Reanim. 1993;18(5):120-2, 125-7.
Central, peripheral and cardiac side-effects of both anticholinergic drugs atropine and glycopyrrolate were compared during the antagonism of muscle relaxation with pyridostigmine. In a randomized, double-blind fashion 50 patients were given 10 micrograms/kg of atropine and 50 were given 5 micrograms/kg of glycopyrrolate with 125 micrograms/kg pyridostigmine intravenously. Continuous Holter ECG-monitoring over 3 hours was performed. The procedure was divided into the following phases: control (5 minutes before application of antagonists), phase I (application of antagonists and the following 5 minutes), phase II (subsequent 30 minutes), phase III (until 3 hours had passed). The first 32 minutes were subdivided into periods of 4 minutes. Analysed were: 1st: The number of patients with supraventricular, junctional and ventricular beats, 2nd: The mean heart rate per period, 3rd: The incidence of central-anticholinergic syndromes and the peripheral antimuscarinic side-effects. Supraventricular beats were found after atropine in 42 patients and after glycopyrrolate in 18 patients (p < 0.001). The differences mainly occurred during phase I (atropine 15 vs. glycopyrrolate 4 p < 0.05) and III (atropine 38 vs. glycopyrrolate 18, p < 0.01). Junctional beats were found after both drugs (atropine 7 vs. glycopyrrolate 10), above all during phase III. Ventricular beats were observed after atropine (21) and glycopyrrolate (18). Atropine as well as glycopyrrolate caused an increased heart rate within the first 4 minutes (atropine 47% vs. glycopyrrolate 27%, p < 0.01). During phase III after atropine, the heart rate decreased below the control value (p < 0.05). None of the patients showed central anticholinergic syndromes after either drug.(ABSTRACT TRUNCATED AT 250 WORDS)
在使用吡啶斯的明拮抗肌肉松弛作用期间,比较了抗胆碱能药物阿托品和格隆溴铵的中枢、外周及心脏副作用。以随机、双盲方式,50例患者静脉给予10微克/千克阿托品,50例患者静脉给予5微克/千克格隆溴铵及125微克/千克吡啶斯的明。进行3小时的动态心电图连续监测。该过程分为以下阶段:对照期(应用拮抗剂前5分钟)、I期(应用拮抗剂及随后5分钟)、II期(接下来30分钟)、III期(直至3小时结束)。前32分钟再细分为4分钟时段。分析内容包括:1. 出现室上性、交界性和室性早搏的患者数量;2. 各时段的平均心率;3. 中枢抗胆碱能综合征及外周抗毒蕈碱副作用的发生率。阿托品组42例患者出现室上性早搏,格隆溴铵组18例患者出现室上性早搏(p<0.001)。差异主要出现在I期(阿托品组15例 vs. 格隆溴铵组4例,p<0.05)和III期(阿托品组38例 vs. 格隆溴铵组18例,p<0.01)。两种药物后均出现交界性早搏(阿托品组7例 vs. 格隆溴铵组10例),主要在III期。观察到阿托品组有21例、格隆溴铵组有18例出现室性早搏。阿托品和格隆溴铵在最初4分钟内均使心率增加(阿托品组47% vs. 格隆溴铵组27%,p<0.01)。阿托品后III期心率降至对照值以下(p<0.05)。两种药物后均无患者出现中枢抗胆碱能综合征。(摘要截断于250字)